A Safety and efficacy study of febuxostat, a non-purine-selective inhibitor of xanthine oxidase, for prevention of tumor lysis syndrome in patients with hematological malignancies.

Trial Profile

A Safety and efficacy study of febuxostat, a non-purine-selective inhibitor of xanthine oxidase, for prevention of tumor lysis syndrome in patients with hematological malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Febuxostat (Primary)
  • Indications Haematological malignancies; Leukaemia; Lymphoma; Tumour lysis syndrome
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 28 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top